Payment overview · 2025
General Payments
$43.17
2 reported records · 2 companies
Healthcare provider profile · identity verified
Paula Vanover
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · CLINTWOOD, VA · NPI 1528725041
Verified facts
What the public records show
CMS Open Payments records show Paula Vanover received $43.17 in general payments during 2025 across 2 reported records.
Gilead Sciences, Inc. accounted for 54.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $23.52 | 54.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $19.65 | 45.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $43.17 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.65 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.65 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 125 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
125 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 789 | 133 |
| Amlodipine Besylate | Amlodipine Besylate | 498 | 105 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 426 | 90 |
| Lisinopril | Lisinopril | 405 | 81 |
| Omeprazole | Omeprazole | 360 | 70 |
| Potassium Chloride | Potassium Chloride | 342 | 67 |
| Atorvastatin Calcium | Atorvastatin Calcium | 320 | 70 |
| Gabapentin | Gabapentin | 312 | 44 |
| Pantoprazole Sodium | Pantoprazole Sodium | 306 | 66 |
| Metformin Hcl | Metformin Hcl | 267 | 51 |
| Losartan Potassium | Losartan Potassium | 265 | 52 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 250 | 41 |
| Furosemide | Furosemide | 248 | 60 |
| Metoprolol Succinate | Metoprolol Succinate | 246 | 43 |
| Montelukast Sodium | Montelukast Sodium | 238 | 45 |
| Tamsulosin Hcl | Tamsulosin Hcl | 236 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 233 | 44 |
| Meloxicam | Meloxicam | 211 | 44 |
| Pravastatin Sodium | Pravastatin Sodium | 198 | 40 |
| Eliquis | Apixaban | 189 | 27 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 187 | 50 |
| Metoprolol Tartrate | Metoprolol Tartrate | 182 | 44 |
| Fluticasone Propionate | Fluticasone Propionate | 166 | 49 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 156 | 26 |
| Simvastatin | Simvastatin | 154 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 148 | 35 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 146 | 23 |
| Sertraline Hcl | Sertraline Hcl | 143 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 135 | 23 |
| Mounjaro | Tirzepatide | 132 | 15 |
| Tramadol Hcl | Tramadol Hcl | 131 | 23 |
| Glipizide | Glipizide | 129 | 23 |
| Atenolol | Atenolol | 126 | 25 |
| Ozempic | Semaglutide | 125 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 124 | 14 |
| Prednisone | Prednisone | 121 | 91 |
| Alprazolam | Alprazolam | 119 | 16 |
| Lorazepam | Lorazepam | 118 | 14 |
| Allopurinol | Allopurinol | 111 | 19 |
| Trazodone Hcl | Trazodone Hcl | 101 | 21 |
| Warfarin Sodium | Warfarin Sodium | 101 | 13 |
| Famotidine | Famotidine | 99 | 26 |
| Ibuprofen | Ibuprofen | 90 | 24 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 89 | 11 |
| Buspirone Hcl | Buspirone Hcl | 88 | 11 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 88 | 13 |
| Carvedilol | Carvedilol | 82 | 20 |
| Finasteride | Finasteride | 81 | 17 |
| Ondansetron Odt | Ondansetron | 78 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 76 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 76 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 71 | 13 |
| Meclizine Hcl | Meclizine Hcl | 70 | 19 |
| Azithromycin | Azithromycin | 69 | 60 |
| Pregabalin | Pregabalin | 68 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 66 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 65 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 64 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 63 | 11 |
| Cephalexin | Cephalexin | 61 | 35 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 60 | 11 |
| Amoxicillin | Amoxicillin | 59 | 45 |
| Ezetimibe | Ezetimibe | 59 | 14 |
| Celecoxib | Celecoxib | 57 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 57 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 56 | suppressed |
| Mirtazapine | Mirtazapine | 55 | 16 |
| Clonazepam | Clonazepam | 53 | suppressed |
| Methylprednisolone | Methylprednisolone | 52 | 42 |
| Spironolactone | Spironolactone | 51 | suppressed |
| Synthroid | Levothyroxine Sodium | 51 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 49 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 49 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | 12 |
| Chlorthalidone | Chlorthalidone | 46 | suppressed |
| Lansoprazole | Lansoprazole | 46 | suppressed |
| Hydrocortisone | Hydrocortisone | 45 | 14 |
| Lidocaine | Lidocaine | 44 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 44 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 43 | suppressed |
| Methocarbamol | Methocarbamol | 43 | 15 |
| Glimepiride | Glimepiride | 42 | suppressed |
| Fluconazole | Fluconazole | 40 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 40 | suppressed |
| Xarelto | Rivaroxaban | 40 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 38 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 35 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 35 | suppressed |
| Mupirocin | Mupirocin | 34 | 21 |
| Torsemide | Torsemide | 34 | suppressed |
| Colchicine | Colchicine | 33 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 32 | suppressed |
| Memantine Hcl | Memantine Hcl | 32 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 31 | suppressed |
| Baclofen | Baclofen | 31 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 31 | suppressed |
| Levofloxacin | Levofloxacin | 31 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 30 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 30 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | 15 |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 29 | suppressed |
| Linzess | Linaclotide | 28 | suppressed |
| Diazepam | Diazepam | 27 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 27 | suppressed |
| Ranolazine Er | Ranolazine | 26 | suppressed |
| Bupropion Xl | Bupropion Hcl | 25 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Nystatin | Nystatin | 25 | 17 |
| Repatha Sureclick | Evolocumab | 24 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 24 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 22 | suppressed |
| Indapamide | Indapamide | 22 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 15 |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 18 |
| Ondansetron Hcl | Ondansetron Hcl | 20 | 12 |
| Cefdinir | Cefdinir | 19 | 17 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 18 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | suppressed |
| Levemir | Insulin Detemir | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 15 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Carisoprodol | Carisoprodol | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Felodipine Er | Felodipine | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Armodafinil | Armodafinil | 12 | suppressed |
| Azathioprine | Azathioprine | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Ciclopirox | Ciclopirox | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 12 | suppressed |
| Nateglinide | Nateglinide | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Zafirlukast | Zafirlukast | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Mesalamine | Mesalamine | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Veo Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $43.17 · 2 records | Gilead Sciences, Inc. | Ozempic, Rybelsus | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error